Showing posts with label industry. Show all posts
Showing posts with label industry. Show all posts

Tuesday, March 28, 2017

Trump’s Pick for FDA Chief Has Drug and Biotech Industry Ties

President Trump’s pick for head of the FDA, Dr. Scott Gottlieb, has taken more than $400,000 from drug makers in the last few years alone, and Gottlieb has deep ties to the pharmaceutical industry. [1]


Gottlieb has testified multiple times on Capitol Hill concerning complex drug pricing issues, and is largely approved of by drug companies and pharmaceutical investors for FDA head. He’s on the boards of directors of several small drug and biotech companies, while also serving as an adviser to GlaxoSmithKline PLC. [2]


Brian Skorney, an investment analyst at Robert W. Baird, wrote in a research note:




“Thank God it’s Gottlieb. We view this as a favorable development for the sector.” [2]


Gottlieb is a former FDA deputy commissioner who has advocated further expediting the approval process for new medical products. He has spent the last decade as a partner at New Enterprise Associates, a large venture fund with investments in the life sciences, medical technology, and healthcare services.


These are just some of his links to the pharmaceutical industry.


Mizuho Securities USA Inc. conducted a survey of 53 pharmaceutical executives and found that 72% favored Gottlieb over other potential candidates.


Michael Carome, director of Public Citizen’s health research group and a physician, said in a statement:


“Gottlieb is entangled in an unprecedented web of Big Pharma ties. He has spent most of his career dedicated to promoting the financial interests of the pharmaceutical industry, and the U.S. Senate must reject him.” [3]


He warns:


“If the Senate does not reject Gottlieb, he will have to be recused from key decisions time and time again, otherwise there is no way to be sure he will put the public’s health over industry profits.”


The Money


Gottlieb has for years been the recipient of consulting fees from Vertex Pharmaceuticals Inc., receiving about $40,000 in 2013, $50,000 in 2014, and $66,000 in 2015. Vertex and the FDA have been in discussions since early 2016 when the FDA denied approval for Kalydeco, a cystic fibrosis drug, for a certain genetic mutation. [1]


GlaxoSmithKline paid Gottlieb $60,000 in 2015 and $100,000 in 2014 in consulting fees. Gottlieb has served as a member of the drug maker’s product investment board for several years. He also received $50,000 in 2015 from Japanese drug company Daiichi Sankyo Inc., and $11,000 in 2013 and $50,000 in 2015 from Novo Nordisk.


Valeant Pharmaceuticals International Inc. paid Gottlieb $9,000 in 2015 and about $1,000 from business unit Salix in 2014. Bristol-Myers Squibb gave him about $2,000 in 2014 and close to $10,000 in 2015.




Gottlieb also received smaller amounts from the following companies:


  • Pfizer

  • AstraZeneca

  • Baxter International

  • Baxter Healthcare

  • Bristol-Myers Squibb

  • Takeda Pharmaceuticals

  • Millennium Pharmaceuticals

  • SI-Bone

  • Insys Therapeutics

Sources:


[1] Market Watch


[2] Reuters


[3] The Hill


NBC News


Raw Story



Storable Food


About Julie Fidler:


Author Image
Julie Fidler is a freelance writer, legal blogger, and the author of Adventures in Holy Matrimony: For Better or the Absolute Worst. She lives in Pennsylvania with her husband and two ridiculously spoiled cats. She occasionally pontificates on her blog.

Wednesday, March 8, 2017

Marijuana industry expected to create 300K jobs in 3-years — provided it stays legal


When President Trump was running for office, he ran on a platform that promised to bring jobs back to America; in particular, jobs from the manufacturing sector that had been siphoned off overseas. In light of that, it’s a shame that the Trump administration has since taken a hostile stance towards recreational marijuana. That’s because the growing marijuana industry could create a ton of jobs.


According to data published by New Frontier Data and highlighted by a recent article from High Times, the marijuana industry could wind up creating 300,000 new jobs by the year 2020. That would be more jobs than are expected to be created by the manufacturing sector. It’s also more jobs than are expected to be generated by utilities or the government. These statistics are based on current growth in the marijuana sector and don’t include states that are likely to legalize marijuana in the near future. They also consider the possibility of a slow down in the growth of the marijuana industry.


Marijuana sales are expected to grow to the tune of $13.3 billion by the year 2020, $11.2 billion of which will be recreational sales. In addition, this financial growth could help support the economy during the next recession. According to Giadha Aguirre De Carcerthe, founder of New Frontier Data, “While we see a potential drop in total number of U.S. jobs created in 2017, as reported by Kiplinger, as well as an overall expected drop in GDP growth, the cannabis industry continues to be a positive contributing factor to growth at a time of potential decline.”


Someone needs to give the Trump administration a reality check. If Trump really wants to rescue the American economy, he needs to back off of the pot issue. Hopefully, the rumors that Jeff Sessions is going to respect states rights on this issue will turn out to be true.


Via Daily Sheeple


Featured Image: Evan/Flickr






Comment Policy: Threats of violence, foul language, bullying, and spam will not be tolerated and may be flagged.